Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,300 | 2023-08-03 00:00:00 UTC | Amgen quarterly revenue rises 6%, profit beats Street estimates | ABBV | https://www.nasdaq.com/articles/amgen-quarterly-revenue-rises-6-profit-beats-street-estimates | null | null | By Deena Beasley
Aug 3 (Reuters) - Amgen AMGN.O, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics HZPN.O, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.
The biotech company, which slig... | Sales of Amjevita, Amgen's biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, totaled $150 million, short of Wall Street expectations of $204 million. By Deena Beasley Aug 3 (Reuters) - Amgen AMGN.O, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon T... | Sales of Amjevita, Amgen's biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, totaled $150 million, short of Wall Street expectations of $204 million. By Deena Beasley Aug 3 (Reuters) - Amgen AMGN.O, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon T... | Sales of Amjevita, Amgen's biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, totaled $150 million, short of Wall Street expectations of $204 million. By Deena Beasley Aug 3 (Reuters) - Amgen AMGN.O, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon T... | Sales of Amjevita, Amgen's biosimilar version of AbbVie's ABBV.N blockbuster arthritis drug Humira, totaled $150 million, short of Wall Street expectations of $204 million. By Deena Beasley Aug 3 (Reuters) - Amgen AMGN.O, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon T... |
22,301 | 2023-08-03 00:00:00 UTC | Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond | ABBV | https://www.nasdaq.com/articles/got-%245000-these-2-stocks-could-be-bargain-buys-for-2023-and-beyond | null | null | The stock market is roaring back in 2023 following a downturn. However, the year hasn't been kind to every company. For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market since January.
Still, there is some good news for investors. Both companies have e... | For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market since January. AbbVie AbbVie's shares are down by 7% since the year started as the company is dealing with arguably its most significant headwind since it became a stand-alone company in 2013. AbbVi... | Meanwhile, AbbVie's declining shares created an excellent entry point for patient investors. For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market since January. AbbVie AbbVie's shares are down by 7% since the year started as the company is dealing wit... | For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market since January. AbbVie AbbVie's shares are down by 7% since the year started as the company is dealing with arguably its most significant headwind since it became a stand-alone company in 2013. AbbVi... | AbbVie's dividend is about as safe as they come, and that's one more reason to add the company's shares to your portfolio. Investors can add 33 shares of AbbVie to their portfolios with $5,000. For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market sinc... |
22,302 | 2023-08-03 00:00:00 UTC | 3 High-Yielding Dividend Stocks to Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-high-yielding-dividend-stocks-to-buy-and-hold-for-decades | null | null | According to a recent Ipsos poll, one in five Americans don't expect to retire, and that's largely because they don't feel they can afford to do so. One way for Americans to improve their financial situation in the future, and to potentially change that outlook, is by investing in dividend stocks. Income-generating inv... | Despite the challenges with Humira's declining sales, AbbVie has a diversified business, and that makes it an ideal stock to buy and hold for not just years but decades. Three companies that make for excellent dividend stocks to buy and hold for decades include AbbVie (NYSE: ABBV), BCE (NYSE: BCE), and Coca-Cola (NYSE:... | Three companies that make for excellent dividend stocks to buy and hold for decades include AbbVie (NYSE: ABBV), BCE (NYSE: BCE), and Coca-Cola (NYSE: KO). AbbVie Drugmaker AbbVie provides investors with an above-average dividend yield of 3.9%, which is more than double the S&P 500 average of 1.5%. Going back to when i... | Three companies that make for excellent dividend stocks to buy and hold for decades include AbbVie (NYSE: ABBV), BCE (NYSE: BCE), and Coca-Cola (NYSE: KO). AbbVie Drugmaker AbbVie provides investors with an above-average dividend yield of 3.9%, which is more than double the S&P 500 average of 1.5%. Going back to when i... | Three companies that make for excellent dividend stocks to buy and hold for decades include AbbVie (NYSE: ABBV), BCE (NYSE: BCE), and Coca-Cola (NYSE: KO). AbbVie Drugmaker AbbVie provides investors with an above-average dividend yield of 3.9%, which is more than double the S&P 500 average of 1.5%. Going back to when i... |
22,303 | 2023-08-02 00:00:00 UTC | AmerisourceBergen sees upbeat annual profit on specialty pharma strength | ABBV | https://www.nasdaq.com/articles/amerisourcebergen-sees-upbeat-annual-profit-on-specialty-pharma-strength | null | null | Adds share movement in paragraph 2, company comment on generic drug prices in paragraph 4, CFO comment in paragraph 6
Aug 2 (Reuters) - Drug distributor AmerisourceBergen ABC.N raised its full-year profit forecast on Wednesday, after strong demand for specialty medicines cushioned a fall in COVID-related drug sales in ... | The company is expected to benefit from the launch of biosimilars, or copies, of AbbVie's ABBV.N blockbuster arthritis treatment Humira in the United States. AmerisourceBergen has been benefiting from specialty drugs - costly medications that treat diseases including cancer and rheumatoid arthritis - at a time when pri... | The company is expected to benefit from the launch of biosimilars, or copies, of AbbVie's ABBV.N blockbuster arthritis treatment Humira in the United States. Adds share movement in paragraph 2, company comment on generic drug prices in paragraph 4, CFO comment in paragraph 6 Aug 2 (Reuters) - Drug distributor Amerisour... | The company is expected to benefit from the launch of biosimilars, or copies, of AbbVie's ABBV.N blockbuster arthritis treatment Humira in the United States. Adds share movement in paragraph 2, company comment on generic drug prices in paragraph 4, CFO comment in paragraph 6 Aug 2 (Reuters) - Drug distributor Amerisour... | The company is expected to benefit from the launch of biosimilars, or copies, of AbbVie's ABBV.N blockbuster arthritis treatment Humira in the United States. Adds share movement in paragraph 2, company comment on generic drug prices in paragraph 4, CFO comment in paragraph 6 Aug 2 (Reuters) - Drug distributor Amerisour... |
22,304 | 2023-08-02 00:00:00 UTC | Bausch + Lomb's Saunders doesn't expect more big deals in the near term | ABBV | https://www.nasdaq.com/articles/bausch-lombs-saunders-doesnt-expect-more-big-deals-in-the-near-term | null | null | By Elissa Welle
Aug 2 (Reuters) - Eye care firm Bausch + Lomb BLCO.TO does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, recently rehired chief executive Brent Saunders said on Wednesday.
Noted dealmaker Saunders has already announced two acquisit... | Saunders previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. By Elissa Welle Aug 2 (Reuters) - Eye care firm Bausch + Lomb BLCO.TO does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, ... | Saunders previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. Noted dealmaker Saunders has already announced two acquisitions since joining the company in March: the deal to buy Xiidra from Novartis NOVN.S in June and a $106.5 million deal for Johnson & Jo... | Saunders previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. By Elissa Welle Aug 2 (Reuters) - Eye care firm Bausch + Lomb BLCO.TO does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, ... | Saunders previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. By Elissa Welle Aug 2 (Reuters) - Eye care firm Bausch + Lomb BLCO.TO does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, ... |
22,305 | 2023-08-02 00:00:00 UTC | Bausch + Lomb posts better than expected Q2 earnings | ABBV | https://www.nasdaq.com/articles/bausch-lomb-posts-better-than-expected-q2-earnings | null | null | By Elissa Welle
Aug 2 (Reuters) - Bausch + Lomb BLCO.TO posted modestly better than expected second-quarter earnings on Wednesday after its new chief executive, Brent Saunders, took the helm in March.
B+L reported revenue of $1.04 billion in the quarter, up from $941 million a year ago. Analysts, on average, expected r... | Saunders, a noted dealmaker, previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. By Elissa Welle Aug 2 (Reuters) - Bausch + Lomb BLCO.TO posted modestly better than expected second-quarter earnings on Wednesday after its new chief executive, Brent Saunder... | Saunders, a noted dealmaker, previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. B+L reported revenue of $1.04 billion in the quarter, up from $941 million a year ago. Excluding items, B+L said it earned $65 million, or 18 cents per share, down from $103 ... | Saunders, a noted dealmaker, previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. By Elissa Welle Aug 2 (Reuters) - Bausch + Lomb BLCO.TO posted modestly better than expected second-quarter earnings on Wednesday after its new chief executive, Brent Saunder... | Saunders, a noted dealmaker, previously helmed and built up Botox maker Allergan before it was acquired by AbbVie ABBV.O for $63 billion in 2020. Excluding items, B+L said it earned $65 million, or 18 cents per share, down from $103 million or 29 cents per share last year, as the company's expenses rose. Still, the ear... |
22,306 | 2023-08-02 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-3 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,307 | 2023-08-01 00:00:00 UTC | Noteworthy ETF Outflows: IWF, ABBV, ADBE, TMO | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-iwf-abbv-adbe-tmo | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $241.9 million dollar outflow -- that's a 0.3% decrease week over week (from 255,950,000 to 255,100,000). ... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Adobe Inc (Symbol: ADBE) is off about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. These ''units'' can be traded back and forth just like stocks, but can also be created or dest... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Adobe Inc (Symbol: ADBE) is off about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one y... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Adobe Inc (Symbol: ADBE) is off about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Adobe Inc (Symbol: ADBE) is off about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... |
22,308 | 2023-08-01 00:00:00 UTC | Better High-Yield Dividend Stock: AbbVie vs. Verizon Communications | ABBV | https://www.nasdaq.com/articles/better-high-yield-dividend-stock%3A-abbvie-vs.-verizon-communications | null | null | If you are looking for a reliable source of income from your investments, you might be interested in high-yield dividend stocks. These are stocks that pay out a large percentage of their earnings to shareholders in the form of dividends.
However, not all high-yield stocks are created equal. Some may have unsustainable ... | While the telecom giant can't offer that much in the way of top-line growth, it sports a substantially higher dividend than AbbVie, and it has a markedly lower payout ratio to boot. Healthcare giant AbbVie (NYSE: ABBV) and telecom behemoth Verizon Communications (NYSE: VZ) are two popular high-yield dividend stocks. Th... | Healthcare giant AbbVie (NYSE: ABBV) and telecom behemoth Verizon Communications (NYSE: VZ) are two popular high-yield dividend stocks. AbbVie currently pays a quarterly dividend of $1.48 per share, which translates to an annual yield of 3.92%. The case for AbbVie AbbVie is a biopharmaceutical company that develops and... | Healthcare giant AbbVie (NYSE: ABBV) and telecom behemoth Verizon Communications (NYSE: VZ) are two popular high-yield dividend stocks. The case for AbbVie AbbVie is a biopharmaceutical company that develops and sells drugs for various therapeutic areas, such as immunology, oncology, neuroscience, and medical aesthetic... | Healthcare giant AbbVie (NYSE: ABBV) and telecom behemoth Verizon Communications (NYSE: VZ) are two popular high-yield dividend stocks. The case for AbbVie AbbVie is a biopharmaceutical company that develops and sells drugs for various therapeutic areas, such as immunology, oncology, neuroscience, and medical aesthetic... |
22,309 | 2023-08-01 00:00:00 UTC | 3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August | ABBV | https://www.nasdaq.com/articles/3-magnificent-high-yield-dividend-stocks-to-buy-hand-over-fist-in-august | null | null | Any time is a good time for income investors to buy dividend stocks. But certain times are better than others for specific stocks.
I think that's the case for several great picks with a new month underway. Here are three magnificent high-yield dividend stocks to buy hand over fist in August.
1. AbbVie
Many investors se... | AbbVie Many investors seemed to have all but thrown in the towel on AbbVie (NYSE: ABBV) until recently. However, AbbVie is now on a roll that could pick up momentum. Sure, the loss of patent exclusivity for AbbVie's blockbuster drug Humira continues to be a major damper on overall revenue. | See the 10 stocks *Stock Advisor returns as of July 27, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie Many investors seemed to have all but thrown in the towel on AbbVie (NYSE: ABBV) until recently. However, AbbVie is now on a ... | As was the case with AbbVie and Brookfield Renewable, describing Enterprise and its yield as "magnificent" isn't an exaggeration. See the 10 stocks *Stock Advisor returns as of July 27, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. Ab... | See the 10 stocks *Stock Advisor returns as of July 27, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie Many investors seemed to have all but thrown in the towel on AbbVie (NYSE: ABBV) until recently. However, AbbVie is now on a ... |
22,310 | 2023-07-31 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-10 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,311 | 2023-07-31 00:00:00 UTC | Surprising Analyst 12-Month Target For HDV | ABBV | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-hdv-0 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core High Dividend ETF ... | iShares Core High Dividend ETF HDV $104.09 $115.63 11.09% Tapestry Inc TPR $43.01 $50.00 16.25% Garmin Ltd GRMN $104.69 $120.00 14.62% AbbVie Inc ABBV $150.85 $170.21 12.84% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of HDV's underlyi... | Three of HDV's underlying holdings with notable upside to their analyst target prices are Tapestry Inc (Symbol: TPR), Garmin Ltd (Symbol: GRMN), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of TPR, GRMN, and ABBV: Combined, TPR, GRMN, and ABBV represent 6.84... | Similarly, GRMN has 14.62% upside from the recent share price of $104.69 if the average analyst target price of $120.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $170.21/share, which is 12.84% above the recent price of $150.85. Three of HDV's underlying holdings with notabl... | Below is a twelve month price history chart comparing the stock performance of TPR, GRMN, and ABBV: Combined, TPR, GRMN, and ABBV represent 6.84% of the iShares Core High Dividend ETF. Three of HDV's underlying holdings with notable upside to their analyst target prices are Tapestry Inc (Symbol: TPR), Garmin Ltd (Symbo... |
22,312 | 2023-07-31 00:00:00 UTC | AbbVie (ABBV) Shares Cross 4% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-4-yield-mark-1 | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.62 on the day. Dividends are particularly important for investors ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.62 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.62 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.62 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.62 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... |
22,313 | 2023-07-31 00:00:00 UTC | AbbVie a Top 25 Dividend Giant With 3.92% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-25-dividend-giant-with-3.92-yield-abbv | null | null | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $34.74B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.92% yield, according to the most recent Dividend Channel ''DividendRank'' report. The report noted a strong quar... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $34.74B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.92% yield, according to the most recent Dividend Channel ''DividendRank'' report. The report noted a strong quar... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $34.74B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.92% yield, according to the most recent Dividend Channel ''DividendRank'' report. The report noted a strong quar... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $34.74B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.92% yield, according to the most recent Dividend Channel ''DividendRank'' report. The annualized dividend paid b... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $34.74B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.92% yield, according to the most recent Dividend Channel ''DividendRank'' report. The report noted a strong quar... |
22,314 | 2023-07-30 00:00:00 UTC | Is It Too Late to Buy InMode Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-inmode-stock-0 | null | null | Shares of InMode (NASDAQ: INMD), a medical technology company focused on the aesthetics industry, recently reached a new 52-week high in anticipation of the second-quarter earnings report the company announced on Thursday, July 27.
InMode's pre-earnings rally drove the stock's 12-month performance up past 65%. After cl... | AbbVie, which markets Botox and the Juvederm brand of fillers, recently reported second-quarter aesthetics sales that rose just 1% year over year. The global noninvasive aesthetic treatment market size was valued at $61.2 billion last year, and it's expected to grow by 15.4% annually through 2030, according to Grand Vi... | AbbVie, which markets Botox and the Juvederm brand of fillers, recently reported second-quarter aesthetics sales that rose just 1% year over year. An outstanding quarter InMode reported second-quarter sales that rose 20% year over year to $136 million. With a recent market cap of just $3.7 billion, InMode is still a re... | AbbVie, which markets Botox and the Juvederm brand of fillers, recently reported second-quarter aesthetics sales that rose just 1% year over year. Shares of InMode (NASDAQ: INMD), a medical technology company focused on the aesthetics industry, recently reached a new 52-week high in anticipation of the second-quarter e... | AbbVie, which markets Botox and the Juvederm brand of fillers, recently reported second-quarter aesthetics sales that rose just 1% year over year. Still underappreciated At recent prices, investors can buy shares of InMode for just 21.6 times the midpoint of management's adjusted earnings estimate for 2023. With a rece... |
22,315 | 2023-07-30 00:00:00 UTC | Want $500 in Super Safe Annual Dividend Income? Invest $9,900 in the Following 3 Dividend Kings | ABBV | https://www.nasdaq.com/articles/want-%24500-in-super-safe-annual-dividend-income-invest-%249900-in-the-following-3-dividend | null | null | Although Wall Street offers few guarantees, history has consistently shown that dividend stocks stand head and shoulders above their competition.
Back in 2013, J.P. Morgan Asset Management, the wealth management division of banking giant JPMorgan Chase, released a report that compared the annualized performance of publ... | AbbVie: 4.18% yield A second Dividend King that can help you bring home $500 in annual dividend income from a $9,900 initial investment (split equally, three ways) is pharmaceutical company AbbVie (NYSE: ABBV). The biggest risk for AbbVie is that it generates a sizable percentage of net sales from a single drug: Humira... | AbbVie: 4.18% yield A second Dividend King that can help you bring home $500 in annual dividend income from a $9,900 initial investment (split equally, three ways) is pharmaceutical company AbbVie (NYSE: ABBV). The biggest risk for AbbVie is that it generates a sizable percentage of net sales from a single drug: Humira... | AbbVie: 4.18% yield A second Dividend King that can help you bring home $500 in annual dividend income from a $9,900 initial investment (split equally, three ways) is pharmaceutical company AbbVie (NYSE: ABBV). The biggest risk for AbbVie is that it generates a sizable percentage of net sales from a single drug: Humira... | Beyond innovation, AbbVie hasn't been afraid to grow through acquisitions. AbbVie: 4.18% yield A second Dividend King that can help you bring home $500 in annual dividend income from a $9,900 initial investment (split equally, three ways) is pharmaceutical company AbbVie (NYSE: ABBV). The biggest risk for AbbVie is tha... |
22,316 | 2023-07-30 00:00:00 UTC | Here's Exactly How I'll Make Over $18,000 in Dividend Income This Year | ABBV | https://www.nasdaq.com/articles/heres-exactly-how-ill-make-over-%2418000-in-dividend-income-this-year | null | null | I don't depend on my investments for income right now. Actually, I've never even paid much attention to how much my portfolio generates in annual income in the past. My practice has been (and still is) to reinvest any dividends or distributions I receive.
However, I recently decided to look at my investment income and ... | See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Apple, Cohen & Steers Infrastructure Fund, DoubleLine Yield Opportunities Fund, Enterprise Products Partners, Innovative Industrial Properties, Microchip Technology, PepsiCo, Pimco Dynamic Income Opportunities Fund, SPD... | See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Apple, Cohen & Steers Infrastructure Fund, DoubleLine Yield Opportunities Fund, Enterprise Products Partners, Innovative Industrial Properties, Microchip Technology, PepsiCo, Pimco Dynamic Income Opportunities Fund, SPD... | See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Apple, Cohen & Steers Infrastructure Fund, DoubleLine Yield Opportunities Fund, Enterprise Products Partners, Innovative Industrial Properties, Microchip Technology, PepsiCo, Pimco Dynamic Income Opportunities Fund, SPD... | Energy stocks Enterprise Products Partners (NYSE: EPD) 7.4% Healthcare stocks AbbVie (NYSE: ABBV) 4.2% Real estate investment trust (REIT) stocks Innovative Industrial Properties (NYSE: IIPR) 9.3% Data source for yields: Yahoo! See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in... |
22,317 | 2023-07-29 00:00:00 UTC | ABBV Quantitative Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-quantitative-stock-analysis-4 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,318 | 2023-07-29 00:00:00 UTC | 3 Stocks Retirees Should Absolutely Love | ABBV | https://www.nasdaq.com/articles/3-stocks-retirees-should-absolutely-love | null | null | Dividend stocks can practically be a retiree's best friend. At least, the right ones can be. Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees should absolutely love now. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE)... | AbbVie bears might point out that its key asset through this period was Humira, a blockbuster immunology medicine that has now lost patent exclusivity and sales of which are declining. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A reliable passive income machine P... | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). AbbVie's solid dividend growth prospects and reliable operations make it a great stock pick for retirees. A reliable passive income machine Prosper Junior Bakiny (AbbVie): Retirees are usually attracted to steady dividen... | AbbVie's solid dividend growth prospects and reliable operations make it a great stock pick for retirees. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A reliable passive income machine Prosper Junior Bakiny (AbbVie): Retirees are usually attracted to steady dividen... | AbbVie's solid dividend growth prospects and reliable operations make it a great stock pick for retirees. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A reliable passive income machine Prosper Junior Bakiny (AbbVie): Retirees are usually attracted to steady dividen... |
22,319 | 2023-07-28 00:00:00 UTC | 3 Biotech Stocks to Buy Before Drug Trials End | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-to-buy-before-drug-trials-end | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
But for those that do, the stock rewards are immense, with huge pricing power and high ret... | The need for new Parkinson’s drugs was underlined recently when drug giant Abbvie’s (NYSE:ABBV) Parkinson’s drug was refused approval. Therefore, the best neurodegenerative disease stocks to buy will be those in late clinical trials who can get their drug approved and then ride the wave of an aging population into more... | The need for new Parkinson’s drugs was underlined recently when drug giant Abbvie’s (NYSE:ABBV) Parkinson’s drug was refused approval. But last year, Amylyx Pharmaceuticals (NASDAQ:AMLX) achieved FDA approval for its ALS drug Relyvrio, despite not having phase 3 clinical trial results. Novo Nordisk (NVO) Source: joreks... | The need for new Parkinson’s drugs was underlined recently when drug giant Abbvie’s (NYSE:ABBV) Parkinson’s drug was refused approval. Therefore, the best neurodegenerative disease stocks to buy will be those in late clinical trials who can get their drug approved and then ride the wave of an aging population into more... | The need for new Parkinson’s drugs was underlined recently when drug giant Abbvie’s (NYSE:ABBV) Parkinson’s drug was refused approval. But last year, Amylyx Pharmaceuticals (NASDAQ:AMLX) achieved FDA approval for its ALS drug Relyvrio, despite not having phase 3 clinical trial results. With Q1 2023 revenue of about $8 ... |
22,320 | 2023-07-28 00:00:00 UTC | 3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend | ABBV | https://www.nasdaq.com/articles/3-high-paying-unusually-active-put-options-to-sell-for-extra-cash-this-weekend | null | null | Friday, at last. Friday, at last! It doesn’t quite have the same ring as Martin Luther King’s iconic words. Perhaps that’s why I’m writing about investments rather than social justice issues.
For my final commentary of the week, I’m looking for three put options to sell for income with an equity kicker. By this, I mea... | It’s More Than Humira When anyone talks about Abbvie (ABBV) these days, there is the prerequisite mentioning of Humira, the company’s top-selling auto-immune disease drug, which has lost its U.S. exclusivity, resulting in lower year-over-year sales. ABBV is up 14% since. In addition to Humira, Abbvie has nine other dru... | It’s More Than Humira When anyone talks about Abbvie (ABBV) these days, there is the prerequisite mentioning of Humira, the company’s top-selling auto-immune disease drug, which has lost its U.S. exclusivity, resulting in lower year-over-year sales. ABBV is up 14% since. In addition to Humira, Abbvie has nine other dru... | It’s More Than Humira When anyone talks about Abbvie (ABBV) these days, there is the prerequisite mentioning of Humira, the company’s top-selling auto-immune disease drug, which has lost its U.S. exclusivity, resulting in lower year-over-year sales. ABBV is up 14% since. In addition to Humira, Abbvie has nine other dru... | It’s More Than Humira When anyone talks about Abbvie (ABBV) these days, there is the prerequisite mentioning of Humira, the company’s top-selling auto-immune disease drug, which has lost its U.S. exclusivity, resulting in lower year-over-year sales. ABBV is up 14% since. In addition to Humira, Abbvie has nine other dru... |
22,321 | 2023-07-28 00:00:00 UTC | Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-azn-sny-abbv-q2-results-mrk-mrna-cancer-jab-in-phase-iii | null | null | This week, AstraZeneca AZN, Sanofi SNY and AbbVie ABBV and Roche announced second-quarter earnings. Merck MRK and partner Moderna announced that their personalized mRNA-based skin cancer vaccine has entered late-stage development. Eli Lilly’s LLY obesity candidate, tirzepatide, demonstrated significant and superior wei... | AbbVie is seeking approval in the EU for epcoritamab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. This week, AstraZeneca AZN, Sanofi SNY and AbbVie ABBV and Roche announced second-quarter earnings. AbbVie beat second-q... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click... | AbbVie Begins Phase III Study on Rinvoq for Hidradenitis Suppurativa: AbbVie announced that the first patient has been dosed in a phase III study evaluating Rinvoq (upadacitinib) for treating adults and adolescents with moderate-to-severe hidradenitis suppurativa, a difficult-to-treat chronic, inflammatory disease. Cli... | This week, AstraZeneca AZN, Sanofi SNY and AbbVie ABBV and Roche announced second-quarter earnings. AbbVie Begins Phase III Study on Rinvoq for Hidradenitis Suppurativa: AbbVie announced that the first patient has been dosed in a phase III study evaluating Rinvoq (upadacitinib) for treating adults and adolescents with ... |
22,322 | 2023-07-28 00:00:00 UTC | S&P Futures Climb Ahead of Key U.S. Inflation Data, Intel Surges on Upbeat Earnings | ABBV | https://www.nasdaq.com/articles/sp-futures-climb-ahead-of-key-u.s.-inflation-data-intel-surges-on-upbeat-earnings | null | null | September S&P 500 futures (ESU23) are trending up +0.46% this morning as market participants braced for a reading on the Federal Reserve’s preferred inflation gauge.
Intel Corporation (INTC) climbed over +7% in pre-market trading after the semiconductor giant reported stronger-than-expected Q2 results and issued upbeat... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. In Thursday’s trading session, Wall Street’s major averages closed lower as bond yields surged following a report by the Nikkei news agency stating that the Bank of Japan ... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. Second-quarter earnings season continues, with investors awaiting new reports from major global companies, including Exxon Mobil (XOM), Procter&Gamble (PG), Aon (AON), and... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. Japan’s Nikkei 225 Stock Index closed lower today as investors grappled with interpreting the Bank of Japan’s decision on Friday to adopt a more flexible approach to its y... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. The French GDP has been reported at +0.5% q/q in the second quarter, stronger than expectations of +0.1% q/q. Japan’s Nikkei 225 Stock Index closed lower today as investor... |
22,323 | 2023-07-28 00:00:00 UTC | S&P Futures Tick Higher Ahead of Key U.S. Inflation Data, Intel Surges on Upbeat Earnings | ABBV | https://www.nasdaq.com/articles/sp-futures-tick-higher-ahead-of-key-u.s.-inflation-data-intel-surges-on-upbeat-earnings | null | null | September S&P 500 futures (ESU23) are trending up +0.35% this morning as market participants braced for a reading on the Federal Reserve’s preferred inflation gauge.
Intel Corporation (INTC) climbed over +7% in pre-market trading after the semiconductor giant reported stronger-than-expected Q2 results and issued upbeat... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. In Thursday’s trading session, Wall Street’s major averages closed lower as bond yields surged following a report by the Nikkei news agency stating that the Bank of Japan ... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. Second-quarter earnings season continues, with investors awaiting new reports from major global companies, including Exxon Mobil (XOM), Procter&Gamble (PG), Aon (AON), and... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. Japan’s Nikkei 225 Stock Index closed lower today as investors grappled with interpreting the Bank of Japan’s decision on Friday to adopt a more flexible approach to its y... | Also, AbbVie Inc (ABBV) gained more than +4% after the company reported stronger-than-expected Q2 results and raised its FY23 adjusted EPS forecast. The French GDP has been reported at +0.5% q/q in the second quarter, stronger than expectations of +0.1% q/q. Japan’s Nikkei 225 Stock Index closed lower today as investor... |
22,324 | 2023-07-28 00:00:00 UTC | The Patent Cliff Is Why AbbVie Is Moving Higher | ABBV | https://www.nasdaq.com/articles/the-patent-cliff-is-why-abbvie-is-moving-higher | null | null | AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. The fear of rapidly declining Humira sales was not offset by hope driven by new products such as Skyrizi and Rinvoq. The takeaway for today is that Humira sales may already be stabilizing, and Skriz... | AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. AbbVie Heals An Ailing Market AbbVie had a solid quarter despite a 25% YOY decline in its leading product, Humira. Analysts Support High-Yielding AbbVie The analyst activity in AbbVie stock is mixed... | Analysts Support High-Yielding AbbVie The analyst activity in AbbVie stock is mixed this year, but the details are bullish. AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. AbbVie Heals An Ailing Market AbbVie had a solid quarter despite a 25% YOY... | AbbVie’s High Yield Helps Support The Price Action As mixed as the outlook for Humira and AbbVie have been over the last 2 years, the stock has always found support because the dividend outlook was reliable. AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped th... | Analysts Support High-Yielding AbbVie The analyst activity in AbbVie stock is mixed this year, but the details are bullish. AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. AbbVie Heals An Ailing Market AbbVie had a solid quarter despite a 25% YOY... |
22,325 | 2023-07-27 00:00:00 UTC | Stocks Rally as Economic News Shows a Resilient U.S. Economy | ABBV | https://www.nasdaq.com/articles/stocks-rally-as-economic-news-shows-a-resilient-u.s.-economy | null | null | What you need to know…
The S&P 500 Index ($SPX) (SPY) today is up +0.62%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.34%.
Stocks this morning are moderately higher, with the S&P 500 climbing to a nearly 16-month high and the Nasdaq 100 posting a 1-week hi... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Semiconductor stocks are climbing today after Samsung Electronics, South Korea’s largest company, reported b... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. T-notes are selling off today from stronger-than-expected U.S. economic reports on Q2 GDP, weekly jobless cl... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Meta Platforms (META) is up more than +6% after reporting Q2 revenue of $32.00 billion, better than the cons... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Sep T-notes today fell to a 2-week low, and the 10-year T-note yield climbed to a 2-week high of 3.956%. A r... |
22,326 | 2023-07-27 00:00:00 UTC | AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-beats-on-q2-earnings-sales-raises-23-view | null | null | AbbVie Inc. ABBV reported adjusted earnings of $2.91 per share for second-quarter 2023, beating the Zacks Consensus Estimate of $2.79. The reported earnings also exceeded the guidance of $2.75-$2.85. However, earnings declined 13.6% year over year.
ABBV’s revenues of $13.87 billion beat the Zacks Consensus Estimate of ... | AbbVie Inc. ABBV reported adjusted earnings of $2.91 per share for second-quarter 2023, beating the Zacks Consensus Estimate of $2.79. ABBV’s revenues of $13.87 billion beat the Zacks Consensus Estimate of $13.52 billion. Quarter in Detail In immunology, AbbVie’s flagship drug Humira recorded a year-over-year sales dec... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 9.8% on an operational basis to $1.48 billion in the quarter, as growth of Venclexta sales, was more than offset by lower sales of Imbruvica. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JN... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 9.8% on an operational basis to $1.48 billion in the quarter, as growth of Venclexta sales, was more than offset by lower sales of Imbruvica. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JN... | AbbVie Inc. ABBV reported adjusted earnings of $2.91 per share for second-quarter 2023, beating the Zacks Consensus Estimate of $2.79. ABBV’s revenues of $13.87 billion beat the Zacks Consensus Estimate of $13.52 billion. Quarter in Detail In immunology, AbbVie’s flagship drug Humira recorded a year-over-year sales dec... |
22,327 | 2023-07-27 00:00:00 UTC | AbbVie (ABBV) Q2 2023 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-2023-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q2 2023 Earnings Call
Jul 27, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Liz Shea
Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, chairman of the board and chief exe... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Sure. AbbVie (NYSE: ABBV) Q2 2023 Earnings Call Jul 27, 2023, 9:00 a.m. Also on the call with me today are Rick Gonzalez, chairman of the board and chief executive officer; Rob Michael, president and chief operating officer; Jeff S... | Also on the call with me today are Rick Gonzalez, chairman of the board and chief executive officer; Rob Michael, president and chief operating officer; Jeff Stewart, executive vice president and chief commercial officer; Scott Reents, executive vice president and chief financer; Carrie Strom, senior vice president, Ab... | Also on the call with me today are Rick Gonzalez, chairman of the board and chief executive officer; Rob Michael, president and chief operating officer; Jeff Stewart, executive vice president and chief commercial officer; Scott Reents, executive vice president and chief financer; Carrie Strom, senior vice president, Ab... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Sure. Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea Rick Gonzalez -- Chairman and Chief Executive Officer Rob Michael -- Vice Chairman and President Jeff Stewart -- Executive Vice President, Chief Comm... |
22,328 | 2023-07-27 00:00:00 UTC | After a 13-Day Winning Streak, the Dow Jones Moves Lower | ABBV | https://www.nasdaq.com/articles/after-a-13-day-winning-streak-the-dow-jones-moves-lower | null | null | What you need to know…
The S&P 500 Index ($SPX) (SPY) today is down -0.51%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%.
Stocks have given back their morning gains and are trending lower this afternoon. If the Dow Jones Industrial Average closes ne... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Semiconductor stocks are climbing today after Samsung Electronics, South Korea’s largest company, reported b... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. T-notes are selling off today from stronger-than-expected U.S. economic reports on Q2 GDP, weekly jobless cl... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Meta Platforms (META) is up more than +6% after reporting Q2 revenue of $32.00 billion, better than the cons... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Sep T-notes today fell to a 2-week low, and the 10-year T-note yield climbed to a 2-week high of 3.956%. A r... |
22,329 | 2023-07-27 00:00:00 UTC | After a 13-Day Winning Streak, the Dow Jones Move Lower | ABBV | https://www.nasdaq.com/articles/after-a-13-day-winning-streak-the-dow-jones-move-lower | null | null | What you need to know…
The S&P 500 Index ($SPX) (SPY) today is down -0.51%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%.
Stocks have given back their morning gains and are trending lower this afternoon. If the Dow Jones Industrial Average closes ne... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Semiconductor stocks are climbing today after Samsung Electronics, South Korea’s largest company, reported b... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. T-notes are selling off today from stronger-than-expected U.S. economic reports on Q2 GDP, weekly jobless cl... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Meta Platforms (META) is up more than +6% after reporting Q2 revenue of $32.00 billion, better than the cons... | AbbVie (ABBV) is up more than +6% after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Sep T-notes today fell to a 2-week low, and the 10-year T-note yield climbed to a 2-week high of 3.956%. A r... |
22,330 | 2023-07-27 00:00:00 UTC | Why AbbVie Stock Is Jumping Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-is-jumping-today | null | null | What happened
Shares of AbbVie (NYSE: ABBV) were jumping 5.5% higher as of 11:24 a.m. ET on Thursday. The nice gain came after the big drugmaker reported its second-quarter results before the market opened.
AbbVie announced Q2 net revenue of nearly $13.9 billion. Although this figure reflected a 4.9% year-over-year dec... | So what The primary narrative about AbbVie this year has been that the company is struggling with the loss of U.S. exclusivity for Humira, its top-selling drug. AbbVie recently won U.S. Food and Drug Administration approval for Rinvoq in treating Crohn's disease. What happened Shares of AbbVie (NYSE: ABBV) were jumping... | What happened Shares of AbbVie (NYSE: ABBV) were jumping 5.5% higher as of 11:24 a.m. AbbVie announced Q2 net revenue of nearly $13.9 billion. AbbVie's non-GAAP (adjusted) EPS in Q2 was $2.91. | So what The primary narrative about AbbVie this year has been that the company is struggling with the loss of U.S. exclusivity for Humira, its top-selling drug. 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of July 27, 2023 ... | AbbVie announced Q2 net revenue of nearly $13.9 billion. What happened Shares of AbbVie (NYSE: ABBV) were jumping 5.5% higher as of 11:24 a.m. AbbVie's non-GAAP (adjusted) EPS in Q2 was $2.91. |
22,331 | 2023-07-27 00:00:00 UTC | AbbVie Gains After Reporting Higher Profit In Q2 | ABBV | https://www.nasdaq.com/articles/abbvie-gains-after-reporting-higher-profit-in-q2 | null | null | (RTTNews) - AbbVie Inc. (ABBV) shares are progressing more than 6 percent on Thursday morning trade after the company reported a surge in second-quarter earnings, compared to the prior year. On a per-share basis, earnings were in line with analysts' view.
The quarterly earnings were $2.024 billion or $1.14 per share co... | (RTTNews) - AbbVie Inc. (ABBV) shares are progressing more than 6 percent on Thursday morning trade after the company reported a surge in second-quarter earnings, compared to the prior year. Richard Gonzalez, chairman and CEO, AbbVie said the strong performance was driven predominantly by its non-Humira business, which... | (RTTNews) - AbbVie Inc. (ABBV) shares are progressing more than 6 percent on Thursday morning trade after the company reported a surge in second-quarter earnings, compared to the prior year. Richard Gonzalez, chairman and CEO, AbbVie said the strong performance was driven predominantly by its non-Humira business, which... | (RTTNews) - AbbVie Inc. (ABBV) shares are progressing more than 6 percent on Thursday morning trade after the company reported a surge in second-quarter earnings, compared to the prior year. For fiscal 2023, AbbVie now expects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable imp... | (RTTNews) - AbbVie Inc. (ABBV) shares are progressing more than 6 percent on Thursday morning trade after the company reported a surge in second-quarter earnings, compared to the prior year. Richard Gonzalez, chairman and CEO, AbbVie said the strong performance was driven predominantly by its non-Humira business, which... |
22,332 | 2023-07-27 00:00:00 UTC | Health Care Sector Update for 07/27/2023: MRSN, BMY, ABBV, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-07-27-2023%3A-mrsn-bmy-abbv-xlv-ibb | null | null | Health care stocks were edging higher pre-bell Thursday with the Health Care Select Sector SPDR Fund (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) recently advancing by 0.3%.
Mersana Therapeutics (MRSN) was shedding almost 74% in value after saying topline data from a clinical trial of upifitamab rilsodotin as ... | AbbVie (ABBV) was over 2% higher after it reported Q2 adjusted earnings of $2.91 per diluted share, down from $3.37 a year earlier but still exceeding the $2.81 forecast from analysts polled by Capital IQ. Health care stocks were edging higher pre-bell Thursday with the Health Care Select Sector SPDR Fund (XLV) up 0.4%... | AbbVie (ABBV) was over 2% higher after it reported Q2 adjusted earnings of $2.91 per diluted share, down from $3.37 a year earlier but still exceeding the $2.81 forecast from analysts polled by Capital IQ. Bristol-Myers Squibb (BMY) was slipping past 3% after it posted Q2 adjusted earnings of $1.75 per diluted share, d... | AbbVie (ABBV) was over 2% higher after it reported Q2 adjusted earnings of $2.91 per diluted share, down from $3.37 a year earlier but still exceeding the $2.81 forecast from analysts polled by Capital IQ. Bristol-Myers Squibb (BMY) was slipping past 3% after it posted Q2 adjusted earnings of $1.75 per diluted share, d... | AbbVie (ABBV) was over 2% higher after it reported Q2 adjusted earnings of $2.91 per diluted share, down from $3.37 a year earlier but still exceeding the $2.81 forecast from analysts polled by Capital IQ. Health care stocks were edging higher pre-bell Thursday with the Health Care Select Sector SPDR Fund (XLV) up 0.4%... |
22,333 | 2023-07-27 00:00:00 UTC | Markets Today: Stocks Soar on the Outlook for a Soft Landing | ABBV | https://www.nasdaq.com/articles/markets-today%3A-stocks-soar-on-the-outlook-for-a-soft-landing | null | null | Morning Markets
September E-Mini S&P 500 futures (ESU23) this morning are up +0.83% at a 16-month high, and Sep Nasdaq 100 E-Mini futures (NQU23) are up +1.47%.
Stock indexes this morning are climbing on speculation the Federal Reserve may be close to ending its 16-month-long policy-tightening cycle. Also, technology ... | AbbVie (ABBV) rose more than +1% in pre-market trading after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Today’s U.S. Earnings Reports (7/27/2023) A O Smith Corp (AOS), AbbVie Inc (ABBV), Amer... | Today’s U.S. Earnings Reports (7/27/2023) A O Smith Corp (AOS), AbbVie Inc (ABBV), American Electric Power Co Inc (AEP), American Tower Corp (AMT), Arthur J Gallagher & Co (AJG), Baxter International Inc (BAX), Boston Scientific Corp (BSX), Bristol-Myers Squibb Co (BMY), Carrier Global Corp (CARR), CBRE Group Inc (CBRE... | Today’s U.S. Earnings Reports (7/27/2023) A O Smith Corp (AOS), AbbVie Inc (ABBV), American Electric Power Co Inc (AEP), American Tower Corp (AMT), Arthur J Gallagher & Co (AJG), Baxter International Inc (BAX), Boston Scientific Corp (BSX), Bristol-Myers Squibb Co (BMY), Carrier Global Corp (CARR), CBRE Group Inc (CBRE... | AbbVie (ABBV) rose more than +1% in pre-market trading after reporting Q2 adjusted EPS of $2.91, better than the consensus of $2.79, and raised its full-year adjusted EPS estimate to $10.90-$11.10 from a prior view of $10.57-$10.97. Today’s U.S. Earnings Reports (7/27/2023) A O Smith Corp (AOS), AbbVie Inc (ABBV), Amer... |
22,334 | 2023-07-27 00:00:00 UTC | AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-beats-q2-earnings-and-revenue-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $3.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 4.30%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.79 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.87 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.54%. AbbVie s... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.87 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.54%. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report To read... | AbbVie (ABBV) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.79 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.87 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.54%. Click to... | AbbVie (ABBV) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.79 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.87 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.54%. AbbVie s... |
22,335 | 2023-07-27 00:00:00 UTC | AbbVie raises profit forecast as Humira stays strong, new drugs impress | ABBV | https://www.nasdaq.com/articles/abbvie-raises-profit-forecast-as-humira-stays-strong-new-drugs-impress | null | null | By Leroy Leo
July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.
Global Humira sales tumbled 25.2% to $4.01 billion ... | By Leroy Leo July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit o... | By Leroy Leo July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit o... | By Leroy Leo July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. AbbVie banks on Skyrizi and Rinvoq to offset Humira... | By Leroy Leo July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit o... |
22,336 | 2023-07-27 00:00:00 UTC | AbbVie Boosts FY23 Outlook As Q2 Results Top Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-boosts-fy23-outlook-as-q2-results-top-estimates | null | null | (RTTNews) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2023.
For fiscal 2023, AbbVie now projects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable im... | (RTTNews) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2023. For fiscal 2023, AbbVie now projects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable im... | (RTTNews) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2023. For fiscal 2023, AbbVie now projects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable im... | For fiscal 2023, AbbVie now projects adjusted earnings in a range of $10.90 to $11.10 per share, which includes an unfavorable impact of $0.23 per share related to the acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2023. (RTTNews) - While reporting financial results for the secon... | For the second quarter, the company reported net income attributable AbbVie of $2.02 billion or $1.14 per share, sharply higher than $924 million or $0.51 per share in the prior-year quarter. (RTTNews) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) ... |
22,337 | 2023-07-27 00:00:00 UTC | AbbVie Q2 23 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q2-23-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 27, 2023, to discuss Q2 23 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 27, 2023, to discuss Q2 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 27, 2023, to discuss Q2 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 27, 2023, to discuss Q2 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 27, 2023, to discuss Q2 23 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... |
22,338 | 2023-07-27 00:00:00 UTC | AbbVie raises annual profit forecast as Humira stays strong, new drugs impress | ABBV | https://www.nasdaq.com/articles/abbvie-raises-annual-profit-forecast-as-humira-stays-strong-new-drugs-impress | null | null | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.
Global Humira sales tumbled 25.2% to $4.01 billion compared with... | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit of $2.91 per s... | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit of $2.91 per s... | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit of $2.91 per s... | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Excluding one-off items, AbbVie reported a profit of $2.91 per s... |
22,339 | 2023-07-27 00:00:00 UTC | Stocks Climb Before the Open as Investors Await Key U.S. GDP Data, Meta Results Boost Sentiment | ABBV | https://www.nasdaq.com/articles/stocks-climb-before-the-open-as-investors-await-key-u.s.-gdp-data-meta-results-boost | null | null | September S&P 500 futures (ESU23) are up +0.59%, and September Nasdaq 100 E-Mini futures (NQU23) are up +1.20% this morning after three major U.S. benchmark indices ended the regular session mixed as market participants digested Federal Reserve Chair Jerome Powell’s comments following the Fed’s widely expected 25 basis... | On the earnings front, major global companies like Mastercard (MA), AbbVie (ABBV), McDonald’s (MCD), Intel (INTC), and Bristol-Myers Squibb (BMY) are set to report their quarterly figures today. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - July 27th Mastercard (MA), AbbVie (... | On the earnings front, major global companies like Mastercard (MA), AbbVie (ABBV), McDonald’s (MCD), Intel (INTC), and Bristol-Myers Squibb (BMY) are set to report their quarterly figures today. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - July 27th Mastercard (MA), AbbVie (... | You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - July 27th Mastercard (MA), AbbVie (ABBV), McDonald’s (MCD), Linde PLC (LIN), Comcast (CMCSA), T-Mobile US (TMUS), Intel (INTC), Honeywell (HON), S&P Global (SPGI), Bristol-Myers Squibb (BMY), Mondelez (MDLZ), American Tower (AMT),... | On the earnings front, major global companies like Mastercard (MA), AbbVie (ABBV), McDonald’s (MCD), Intel (INTC), and Bristol-Myers Squibb (BMY) are set to report their quarterly figures today. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - July 27th Mastercard (MA), AbbVie (... |
22,340 | 2023-07-27 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-45 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,341 | 2023-07-26 00:00:00 UTC | 3 Stocks to Buy While They Are on Sale | ABBV | https://www.nasdaq.com/articles/3-stocks-to-buy-while-they-are-on-sale-6 | null | null | There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.
The good news, though, is that not every stock has a sky-high valuation. Some are actually available at bargain prices. Here are thre... | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 13 times forward earnings. Why does AbbVie have such a low valuation? AbbVie's top-selling drug now faces biosimilar competition in the U.S. and in Europe. | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 13 times forward earnings. Why does AbbVie have such a low valuation? AbbVie's top-selling drug now faces biosimilar competition in the U.S. and in Europe. | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 13 times forward earnings. Why does AbbVie have such a low valuation? AbbVie's top-selling drug now faces biosimilar competition in the U.S. and in Europe. | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 13 times forward earnings. Why does AbbVie have such a low valuation? AbbVie's top-selling drug now faces biosimilar competition in the U.S. and in Europe. |
22,342 | 2023-07-26 00:00:00 UTC | The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-toyota-deere-starbucks-abbvie-and-dexcom | null | null | For Immediate Release
Chicago, IL – July 26, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Toyota Motor Corp. TM, Deere ... | Stocks recently featured in the blog include: Toyota Motor Corp. TM, Deere & Co. DE, Starbucks Corp. SBUX, AbbVie Inc. ABBV and DexCom, Inc. DXCM. Other noteworthy reports we are featuring today include AbbVie Inc. and DexCom, Inc. Why Haven’t You Looked at Zacks' Top Stocks? Click to get this free report Toyota Motor ... | Stocks recently featured in the blog include: Toyota Motor Corp. TM, Deere & Co. DE, Starbucks Corp. SBUX, AbbVie Inc. ABBV and DexCom, Inc. DXCM. Click to get this free report Toyota Motor Corporation (TM) : Free Stock Analysis Report Starbucks Corporation (SBUX) : Free Stock Analysis Report Deere & Company (DE) : Fre... | Click to get this free report Toyota Motor Corporation (TM) : Free Stock Analysis Report Starbucks Corporation (SBUX) : Free Stock Analysis Report Deere & Company (DE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Za... | Stocks recently featured in the blog include: Toyota Motor Corp. TM, Deere & Co. DE, Starbucks Corp. SBUX, AbbVie Inc. ABBV and DexCom, Inc. DXCM. Other noteworthy reports we are featuring today include AbbVie Inc. and DexCom, Inc. Why Haven’t You Looked at Zacks' Top Stocks? Click to get this free report Toyota Motor ... |
22,343 | 2023-07-26 00:00:00 UTC | Looking to Get Richer? These 2 Dividend Stocks Have Doubled in 5 Years | ABBV | https://www.nasdaq.com/articles/looking-to-get-richer-these-2-dividend-stocks-have-doubled-in-5-years | null | null | As an investment class, dividend growth stocks tend to produce better investment outcomes than their non-dividend growth counterparts. This shouldn't come as a surprise considering that consistently handing out dividend raises requires growing profits, which leads to share price appreciation over time.
Here are two div... | Along with additional indications that the drugs are expected to snag in the future, AbbVie's management believes combined peak annual sales for the pair could top $21 billion as soon as 2027. AbbVie: So much more than Humira The pharmaceutical company AbbVie (NYSE: ABBV) has done exceptionally well for shareholders in... | AbbVie: So much more than Humira The pharmaceutical company AbbVie (NYSE: ABBV) has done exceptionally well for shareholders in the past half-decade: A $10,000 investment made at this time in 2018 would now be worth about $19,760 with dividends reinvested. Accounting for 36.8% of AbbVie's $58.1 billion in 2022 net reve... | AbbVie: So much more than Humira The pharmaceutical company AbbVie (NYSE: ABBV) has done exceptionally well for shareholders in the past half-decade: A $10,000 investment made at this time in 2018 would now be worth about $19,760 with dividends reinvested. Accounting for 36.8% of AbbVie's $58.1 billion in 2022 net reve... | Along with additional indications that the drugs are expected to snag in the future, AbbVie's management believes combined peak annual sales for the pair could top $21 billion as soon as 2027. Like AbbVie, a $10,000 investment in Elevance Health made five years ago would now be valued north of $20,300 with dividends re... |
22,344 | 2023-07-26 00:00:00 UTC | PREVIEW-AbbVie may see less pain from Humira sales decline as rival lags | ABBV | https://www.nasdaq.com/articles/preview-abbvie-may-see-less-pain-from-humira-sales-decline-as-rival-lags | null | null | By Leroy Leo
July 26 (Reuters) - AbbVie Inc ABBV.N is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.
Humira sales are likely to decline when the company reports on Thursday but that would m... | By Leroy Leo July 26 (Reuters) - AbbVie Inc ABBV.N is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction. Humira sales are likely to decline when the company reports on Thursday but that would m... | Analysts on average expect AbbVie to generate $13.8 billion in global sales of Humira this year, sharply lower than $21.2 billion generated in 2022. ** 16 analysts, on average, forecast AbbVie's second-quarter revenue to be $13.52 billion, according to Refinitiv, compared with $14.58 billion that the company reported a... | Analysts on average expect AbbVie to generate $13.8 billion in global sales of Humira this year, sharply lower than $21.2 billion generated in 2022. ** 16 analysts, on average, forecast AbbVie's second-quarter revenue to be $13.52 billion, according to Refinitiv, compared with $14.58 billion that the company reported a... | Humira sales are likely to decline when the company reports on Thursday but that would mostly be due to the discounts AbbVie has offered to shield itself from prescription share erosion, analysts have said. By Leroy Leo July 26 (Reuters) - AbbVie Inc ABBV.N is likely to beat Wall Street sales estimates for Humira in th... |
22,345 | 2023-07-26 00:00:00 UTC | Pre-Market Earnings Report for July 27, 2023 : MA, ABBV, MCD, LIN, CMCSA, HON, SPGI, BMY, AMT, HCA, BSX, NOC | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-27-2023-%3A-ma-abbv-mcd-lin-cmcsa-hon-spgi-bmy-amt-hca | null | null | The following companies are expected to report earnings prior to market open on 07/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Mastercard Incorporated (MA)is reporting for the quarter ending June 30, 2023. The financial transactions company's consensus earnings per share forecas... | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.05 vs. an industry ratio of 22.40. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.05 vs. an industry ratio of 22.40. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.05 vs. an industry ratio of 22.40. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.05 vs. an industry ratio of 22.40. |
22,346 | 2023-07-25 00:00:00 UTC | ABBV Quantitative Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-quantitative-stock-analysis-3 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,347 | 2023-07-25 00:00:00 UTC | Zacks Investment Ideas feature highlights: Chipotle Mexican Grill, Visa and AbbVie | ABBV | https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-chipotle-mexican-grill-visa-and-abbvie | null | null | For Immediate Release
Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature highlights Chipotle Mexican Grill CMG, Visa V and AbbVie ABBV.
3 Non-Tech Reports to Watch This Week
Earnings season is rapidly picking up pace, with a wide variety of companies scheduled to unveil quarterly results this week.
And... | For Immediate Release Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature highlights Chipotle Mexican Grill CMG, Visa V and AbbVie ABBV. While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including those from Chipotle Mexican Grill, Visa and... | For Immediate Release Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature highlights Chipotle Mexican Grill CMG, Visa V and AbbVie ABBV. AbbVie: July 27th AbbVie shares have faced adverse price action year-to-date, down roughly 4% and widely underperforming relative to the general market. Click to get t... | Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature... | For Immediate Release Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature highlights Chipotle Mexican Grill CMG, Visa V and AbbVie ABBV. While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including those from Chipotle Mexican Grill, Visa and... |
22,348 | 2023-07-25 00:00:00 UTC | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp-8 | null | null | If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Dynamic Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.
Retail and institutional investors increasingly turn to passively managed ETFs because they... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 6.11% of total assets, followed by Abbvie Inc (ABBV) and Amgen Inc (AMGN). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Fr... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharma... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharma... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 6.11% of total assets, followed by Abbvie Inc (ABBV) and Amgen Inc (AMGN). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Fr... |
22,349 | 2023-07-25 00:00:00 UTC | AbbVie's RINVOQ Gets Regulatory Nod In Canada For Yet Another Indication | ABBV | https://www.nasdaq.com/articles/abbvies-rinvoq-gets-regulatory-nod-in-canada-for-yet-another-indication | null | null | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada.
The drug has now been received approval in Canada to treat adults with moderately to severely active ulcerative colitis who have demons... | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada. In pre-market activity, shares of AbbVie are trading at $142.76, down 0.29% on the New York Stock Exchange. The drug has now been recei... | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada. In pre-market activity, shares of AbbVie are trading at $142.76, down 0.29% on the New York Stock Exchange. The drug has now been recei... | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada. In pre-market activity, shares of AbbVie are trading at $142.76, down 0.29% on the New York Stock Exchange. The drug has now been recei... | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada. In pre-market activity, shares of AbbVie are trading at $142.76, down 0.29% on the New York Stock Exchange. The drug has now been recei... |
22,350 | 2023-07-25 00:00:00 UTC | Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline | ABBV | https://www.nasdaq.com/articles/earnings-preview%3A-pfizer-pfe-q2-earnings-expected-to-decline | null | null | Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that co... | An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $2.82 for the quarter ended June 2023. Over the last 30 days, the consensus EPS estimate for AbbVie has been revised 0.2% up to the current level. When combined... | When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com clic... | An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $2.82 for the quarter ended June 2023. Over the last 30 days, the consensus EPS estimate for AbbVie has been revised 0.2% up to the current level. When combined... | When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $2.... |
22,351 | 2023-07-25 00:00:00 UTC | Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales? | ABBV | https://www.nasdaq.com/articles/will-abbvies-abbv-new-drugs-make-up-for-low-humira-sales | null | null | AbbVie’s ABBV second-quarter revenues are likely to be driven by product revenues generated from its newer immunology drugs, Rinvoq and Skyrizi.
Around half of the company’s revenues is expected to be generated from its immunology franchise, consisting of three blockbuster drugs — Humira, Rinvoq and Skyrizi. Humira, wh... | AbbVie’s ABBV second-quarter revenues are likely to be driven by product revenues generated from its newer immunology drugs, Rinvoq and Skyrizi. AbbVie’s stock has lost 11.4% in the year so far against the industry‘s 3.3% growth. Image Source: Zacks Investment Research To make up for the falling Humira sales, AbbVie is... | Image Source: Zacks Investment Research To make up for the falling Humira sales, AbbVie is focused on launching its newer immunology drugs — Skyrizi and Rinvoq — across Humira's major indications and a distinct new indication, atopic dermatitis. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stock... | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Werewolf Therapeutics, Inc. (HOWL) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie’s ABBV second-quar... | AbbVie’s ABBV second-quarter revenues are likely to be driven by product revenues generated from its newer immunology drugs, Rinvoq and Skyrizi. AbbVie’s stock has lost 11.4% in the year so far against the industry‘s 3.3% growth. Image Source: Zacks Investment Research To make up for the falling Humira sales, AbbVie is... |
22,352 | 2023-07-25 00:00:00 UTC | William Blair Initiates Coverage of Abbvie (ABBV) with Market Perform Recommendation | ABBV | https://www.nasdaq.com/articles/william-blair-initiates-coverage-of-abbvie-abbv-with-market-perform-recommendation | null | null | Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation.
Analyst Price Forecast Suggests 17.60% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The ... | Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 17.60... | Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation. Analyst Price Forecast Suggests 17.60% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of ... | Abbvie Declares $1.48 Dividend On June 22, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation. Analyst Price Forecast Suggests 17.60% Upside As of ... | Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation. Analyst Price Forecast Suggests 17.60% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of ... |
22,353 | 2023-07-25 00:00:00 UTC | Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks | ABBV | https://www.nasdaq.com/articles/q2-earnings-season-scorecard-and-analyst-reports-for-toyota-deere-starbucks | null | null | Tuesday, July 25, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time update on the ongoing Q2 earnings season and new research reports on 16 major stocks, including Toyota Motor Corporation (TM), Deere & Company (DE) and Starbucks Corporatio... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Toyota Motor's (TM) Prospects Solid on Electrification Push Deere (DE) Gains from Strong Demand and Strategic Actions Store & Comps Growth Aid Starbucks (SBUX), High Cost Ail Featured Reports AbbVie's (ABB... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Toyota Motor's (TM) Prospects Solid on Electrification Push Deere (DE) Gains from Strong Demand and Strategic Actions Store & Comps Growth Aid Starbucks (SBUX), High Cost Ail Featured Reports AbbVie's (ABB... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Toyota Motor's (TM) Prospects Solid on Electrification Push Deere (DE) Gains from Strong Demand and Strategic Actions Store & Comps Growth Aid Starbucks (SBUX), High Cost Ail Featured Reports AbbVie's (ABB... | Other noteworthy reports we are featuring today include AbbVie Inc. (ABBV), Equinor ASA (EQNR) and DexCom, Inc. (DXCM). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Toyota Motor's (TM) Prospects Solid on Electrification Push Deere (DE) Gains from Str... |
22,354 | 2023-07-24 00:00:00 UTC | Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-dynamic-large-cap-value-etf-pwv-a-strong-etf-right-now-8 | null | null | Making its debut on 03/03/2005, smart beta exchange traded fund Invesco Dynamic Large Cap Value ETF (PWV) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitaliza... | Taking into account individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of the fund's total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock ... | Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russ... | Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russ... | Taking into account individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of the fund's total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock ... |
22,355 | 2023-07-24 00:00:00 UTC | 3 Non-Tech Reports to Watch This Week | ABBV | https://www.nasdaq.com/articles/3-non-tech-reports-to-watch-this-week | null | null | Earnings season is rapidly picking up pace, with a wide variety of companies scheduled to unveil quarterly results this week.
And next week, we’ll have an even bigger slate.
On the minds of many this week is big tech earnings, with several heavyweights slated to report.
While many remain focused on tech, there are seve... | While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including those from Chipotle Mexican Grill CMG, Visa V, and AbbVie ABBV. Image Source: Zacks Investment Research Bottom Line It’s not just all about tech earnings this week, with the likes of Chipotle Mexi... | Image Source: Zacks Investment Research AbbVie: July 27th AbbVie shares have faced adverse price action year-to-date, down roughly 4% and widely underperforming relative to the general market. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG) : Free Stock Analys... | Image Source: Zacks Investment Research Bottom Line It’s not just all about tech earnings this week, with the likes of Chipotle Mexican Grill CMG, Visa V, and AbbVie ABBV all on the docket to report. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG) : Free Stock... | While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including those from Chipotle Mexican Grill CMG, Visa V, and AbbVie ABBV. Image Source: Zacks Investment Research AbbVie: July 27th AbbVie shares have faced adverse price action year-to-date, down roughly 4... |
22,356 | 2023-07-24 00:00:00 UTC | The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos | ABBV | https://www.nasdaq.com/articles/the-7-best-dividend-stocks-to-protect-your-portfolio-from-global-chaos | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the world seemingly poised for a massive conflict, market partici... | AbbVie (ABBV) Source: Shutterstock Another pharmaceutical idea for best dividend stocks, AbbVie (NYSE:ABBV) benefits from reliable relevance. Further, I appreciate AbbVie specifically because of its Allergan acquisition, which subsequently brought Botox under the acquirer’s control. As a bonus, ABBV trades at forward e... | AbbVie (ABBV) Source: Shutterstock Another pharmaceutical idea for best dividend stocks, AbbVie (NYSE:ABBV) benefits from reliable relevance. Further, I appreciate AbbVie specifically because of its Allergan acquisition, which subsequently brought Botox under the acquirer’s control. As a bonus, ABBV trades at forward e... | AbbVie (ABBV) Source: Shutterstock Another pharmaceutical idea for best dividend stocks, AbbVie (NYSE:ABBV) benefits from reliable relevance. Further, I appreciate AbbVie specifically because of its Allergan acquisition, which subsequently brought Botox under the acquirer’s control. As a bonus, ABBV trades at forward e... | AbbVie (ABBV) Source: Shutterstock Another pharmaceutical idea for best dividend stocks, AbbVie (NYSE:ABBV) benefits from reliable relevance. Further, I appreciate AbbVie specifically because of its Allergan acquisition, which subsequently brought Botox under the acquirer’s control. As a bonus, ABBV trades at forward e... |
22,357 | 2023-07-24 00:00:00 UTC | IWF, ABBV, TMO, NOW: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/iwf-abbv-tmo-now%3A-etf-outflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $726.3 million dollar outflow -- that's a 1.0% decrease week over week (from 258,550,000 to 255,950,000). ... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.1%, and ServiceNow Inc (Symbol: NOW) is up by about 0.2%. These ''units'' can be traded back and forth just like stocks, but can also be created or destro... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.1%, and ServiceNow Inc (Symbol: NOW) is up by about 0.2%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one yea... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.1%, and ServiceNow Inc (Symbol: NOW) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.1%, and ServiceNow Inc (Symbol: NOW) is up by about 0.2%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one yea... |
22,358 | 2023-07-23 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-44 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,359 | 2023-07-21 00:00:00 UTC | 3 High-Yield Dividend Stocks I Plan on Holding Forever | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-i-plan-on-holding-forever | null | null | Buy and hold. The first word in this investing strategy is easy to do, but it's a different story for the second one.
Granted, some stocks don't deserve to be held for very long. Management teams can lose investors' confidence or industry dynamics can change. There are many factors that can cause a stock to fall out of... | AbbVie You can put a crown on AbbVie (NYSE: ABBV). Instead, the context of what's going on makes me even more confident about AbbVie over the long run. AbbVie's top-selling drug, Humira, at long last began to face biosimilar competition in the U.S. earlier this year. | See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, and Brookfield Renewable Partners. AbbVie You can put a crown on AbbVie (NYSE: ABBV). Instead, the context of what's going on makes me... | See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, and Brookfield Renewable Partners. AbbVie You can put a crown on AbbVie (NYSE: ABBV). Instead, the context of what's going on makes me... | Instead, the context of what's going on makes me even more confident about AbbVie over the long run. See the 10 stocks *Stock Advisor returns as of July 17, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, and Brookfield Renewable Partners... |
22,360 | 2023-07-21 00:00:00 UTC | AbbVie/Genmab's Diffuse Large B-cell Lymphoma Drug A Step Away From Approval In Europe | ABBV | https://www.nasdaq.com/articles/abbvie-genmabs-diffuse-large-b-cell-lymphoma-drug-a-step-away-from-approval-in-europe | null | null | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults.
T... | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults. E... | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults. T... | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults. T... | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults. T... |
22,361 | 2023-07-21 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-9 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,362 | 2023-07-20 00:00:00 UTC | Noteworthy Thursday Option Activity: ORLY, REGN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-orly-regn-abbv | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in O'Reilly Automotive, Inc. (Symbol: ORLY), where a total of 2,120 contracts have traded so far, representing approximately 212,000 underlying shares. That amounts to about 53.8% of ORLY's average daily trading volume ... | Particularly high volume was seen for the $140 strike call option expiring July 21, 2023, with 2,278 contracts trading so far today, representing approximately 227,800 underlying shares of ABBV. Below is a chart showing REGN's trailing twelve month trading history, with the $780 strike highlighted in orange: And AbbVie... | Below is a chart showing REGN's trailing twelve month trading history, with the $780 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,481 contracts thus far today. That number of contracts represents approximately 2.9 million underlying shares, working out to a sizeable 51.... | Below is a chart showing ABBV's trailing twelve month trading history, with the $140 strike highlighted in orange: For the various different available expirations for ORLY options, REGN options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing REGN's trailing twelve month trading history, with t... | Below is a chart showing ABBV's trailing twelve month trading history, with the $140 strike highlighted in orange: For the various different available expirations for ORLY options, REGN options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing REGN's trailing twelve month trading history, with t... |
22,363 | 2023-07-20 00:00:00 UTC | Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for | ABBV | https://www.nasdaq.com/articles/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings%3A-what-to-look-out-for | null | null | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price i... | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent a... | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent a... | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent a... | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent a... |
22,364 | 2023-07-20 00:00:00 UTC | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-wisdomtree-u.s.-high-dividend-etf-dhs-be-on-your-investing-radar-8 | null | null | Launched on 06/16/2006, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.16 billion, making it one of the average sized E... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,365 | 2023-07-20 00:00:00 UTC | 3 of the Best Dividend Stocks to Buy for Passive Income Growth | ABBV | https://www.nasdaq.com/articles/3-of-the-best-dividend-stocks-to-buy-for-passive-income-growth | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount. The goal is to find reliable blue-chip companies that pay above-... | Along with its strong pipeline of upcoming drugs, AbbVie has a portfolio that provides long-term investors with a positive outlook for continued income growth and stability, something that’s hard to come by in the biotech sector. AbbVie (ABBV) AbbVie (NYSE:ABBV) stands out among pharmaceutical stocks for its strong div... | Along with its strong pipeline of upcoming drugs, AbbVie has a portfolio that provides long-term investors with a positive outlook for continued income growth and stability, something that’s hard to come by in the biotech sector. AbbVie (ABBV) AbbVie (NYSE:ABBV) stands out among pharmaceutical stocks for its strong div... | AbbVie (ABBV) AbbVie (NYSE:ABBV) stands out among pharmaceutical stocks for its strong dividend. The loss of patent exclusivity for Humira has impacted ABBV stock, leading to concerns about future sales and earnings. Moreover, AbbVie’s acquisition of Allergan has given it control over Botox, a popular anti-aging treatm... | AbbVie (ABBV) AbbVie (NYSE:ABBV) stands out among pharmaceutical stocks for its strong dividend. The loss of patent exclusivity for Humira has impacted ABBV stock, leading to concerns about future sales and earnings. Moreover, AbbVie’s acquisition of Allergan has given it control over Botox, a popular anti-aging treatm... |
22,366 | 2023-07-19 00:00:00 UTC | Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-schwab-u.s.-dividend-equity-etf-schd-be-on-your-investing-radar-8 | null | null | Launched on 10/20/2011, the Schwab U.S. Dividend Equity ETF (SCHD) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Charles Schwab. It has amassed assets over $48.48 billion, making it one of the largest ETF... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 4.34% of total assets, followed by Pepsico Inc (PEP) and Cisco Systems Inc (CSCO). Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) :... | Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ET... | Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ET... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 4.34% of total assets, followed by Pepsico Inc (PEP) and Cisco Systems Inc (CSCO). Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) :... |
22,367 | 2023-07-19 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-2 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,368 | 2023-07-18 00:00:00 UTC | The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-walmart-abbvie-nike-uber-and-paypal | null | null | For Immediate Release
Chicago, IL – July 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. WMT, AbbVie Inc.... | Stocks recently featured in the blog include: Walmart Inc. WMT, AbbVie Inc. ABBV, Nike, Inc. NKE, Uber Technologies, Inc. UBER and PayPal Holdings, Inc. PYPL. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Walmart, AbbVie and Nike The Zacks Research Daily presents the best research output of ou... | Stocks recently featured in the blog include: Walmart Inc. WMT, AbbVie Inc. ABBV, Nike, Inc. NKE, Uber Technologies, Inc. UBER and PayPal Holdings, Inc. PYPL. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Walmart, AbbVie and Nike The Zacks Research Daily presents the best research output of ou... | Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Walmart, AbbVie and Nike The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., AbbVie Inc. and Nike, Inc. Click to get this f... | Stocks recently featured in the blog include: Walmart Inc. WMT, AbbVie Inc. ABBV, Nike, Inc. NKE, Uber Technologies, Inc. UBER and PayPal Holdings, Inc. PYPL. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Walmart, AbbVie and Nike The Zacks Research Daily presents the best research output of ou... |
22,369 | 2023-07-18 00:00:00 UTC | Softbank-backed Neumora's depression drug cuts symptoms in mid-stage trial | ABBV | https://www.nasdaq.com/articles/softbank-backed-neumoras-depression-drug-cuts-symptoms-in-mid-stage-trial | null | null | July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial, the company said on Tuesday.
Neumora, whose investors include SoftBank Vision Fund and Amgen AMGN.O, said it wo... | Separately, the drug developer named former AbbVie ABBV.N executive Henry Gosebruch its new CEO, replacing co-founder Paul Berns. July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in ... | Separately, the drug developer named former AbbVie ABBV.N executive Henry Gosebruch its new CEO, replacing co-founder Paul Berns. July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in ... | Separately, the drug developer named former AbbVie ABBV.N executive Henry Gosebruch its new CEO, replacing co-founder Paul Berns. July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in ... | Separately, the drug developer named former AbbVie ABBV.N executive Henry Gosebruch its new CEO, replacing co-founder Paul Berns. July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in ... |
22,370 | 2023-07-17 00:00:00 UTC | 3 Dividend Stocks That Still Make Sense in 2023 | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-still-make-sense-in-2023 | null | null | It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. Dividend-paying stocks give investors a reward for simply holding on to the stock. That money can be used to reinvest into the stock. This can either add to your gains or help to offset your losses.
As many div... | The big issue souring investors on AbbVie is the patent expiration on its cash cow drug, Humira. An Undervalued Dividend King Looks to Retain Its Crown Next on this list of dividend stocks to own in 2023 is AbbVie, Inc. (NYSE: ABBV). As of this writing, ABBV stock is down approximately 26% in 2023 and 17% in the last 1... | An Undervalued Dividend King Looks to Retain Its Crown Next on this list of dividend stocks to own in 2023 is AbbVie, Inc. (NYSE: ABBV). As of this writing, ABBV stock is down approximately 26% in 2023 and 17% in the last 12 months. The big issue souring investors on AbbVie is the patent expiration on its cash cow drug... | An Undervalued Dividend King Looks to Retain Its Crown Next on this list of dividend stocks to own in 2023 is AbbVie, Inc. (NYSE: ABBV). As of this writing, ABBV stock is down approximately 26% in 2023 and 17% in the last 12 months. The big issue souring investors on AbbVie is the patent expiration on its cash cow drug... | AbbVie is also a dividend king, which means it has increased its dividend for at least 50 consecutive years. An Undervalued Dividend King Looks to Retain Its Crown Next on this list of dividend stocks to own in 2023 is AbbVie, Inc. (NYSE: ABBV). As of this writing, ABBV stock is down approximately 26% in 2023 and 17% i... |
22,371 | 2023-07-17 00:00:00 UTC | Top Analyst Reports for Walmart, AbbVie & Nike | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-walmart-abbvie-nike | null | null | Monday, July 17, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE). These research reports have been hand-picked from the roughly 70 reports ... | Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE). Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-6.1% vs. +9.7%). Nonetheless, though revenues are expected to decline in ... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Walmart (WMT) Benefits from Impressive E-Commerce Operations AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Improved Traffic & Digital Trends Aid NIKE (NKE) Direct Featured Reports Uber (UBER) Rid... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Walmart (WMT) Benefits from Impressive E-Commerce Operations AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Improved Traffic & Digital Trends Aid NIKE (NKE) Direct Featured Reports Uber (UBER) Rid... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Walmart (WMT) Benefits from Impressive E-Commerce Operations AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Improved Traffic & Digital Trends Aid NIKE (NKE) Direct Featured Reports Uber (UBER) Rid... |
22,372 | 2023-07-17 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-8 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned -1.9%, compared to the Zacks S&P 500 composite's +3.2% change. During thi... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals indus... | Last Reported Results and Surprise History AbbVie reported revenues of $12.23 billion in the last reported quarter, representing a year-over-year change of -9.7%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVi... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 1.3%. AbbVie is expected to post earnings of $2.92 per share for the current quarter, representing a year-over-year change of -13.4%. |
22,373 | 2023-07-16 00:00:00 UTC | 3 Dividend Growth Stocks to Buy and Hold | ABBV | https://www.nasdaq.com/articles/3-dividend-growth-stocks-to-buy-and-hold | null | null | Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to where the puck is going to be, not where it has been."
His idea is applicable in lots of areas. Income investors could ce... | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Upward and onward Keith Speights (AbbVie): One of the first things you'll probably notice about AbbVie is its juicy dividend yield of over 4.4%. AbbVie belongs to the elite group of stocks known as Dividend Kings. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Upward and onward Keith Speights (AbbVie): One of the first things you'll probably notice about AbbVie is its juicy dividend yield of over 4.4%. AbbVie belongs to the elite group of stocks known as Dividend Kings. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Upward and onward Keith Speights (AbbVie): One of the first things you'll probably notice about AbbVie is its juicy dividend yield of over 4.4%. AbbVie belongs to the elite group of stocks known as Dividend Kings. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). Upward and onward Keith Speights (AbbVie): One of the first things you'll probably notice about AbbVie is its juicy dividend yield of over 4.4%. AbbVie belongs to the elite group of stocks known as Dividend Kings. |
22,374 | 2023-07-16 00:00:00 UTC | 7 Spectacular High-Yield Dividend Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/7-spectacular-high-yield-dividend-stocks-to-buy-in-july | null | null | You don't have to settle for puny dividend income. Thousands of stocks offer dividends. Many of them, though, have dividend yields that don't amount to a hill of beans.
What if you could invest in solid companies with dividends that could really boost your income? The good news is that you can. Here are seven spectacul... | AbbVie fully expects to return to solid growth once it moves past the initial impact of the loss of exclusivity for Humira. AbbVie AbbVie's (NYSE: ABBV) dividend yield currently stands at nearly 4.4%. Don't worry about declining sales for AbbVie's huge blockbuster Humira. | See the 10 stocks *Stock Advisor returns as of July 10, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie AbbVie's (NYSE: ABBV) dividend yield currently stands at nearl... | See the 10 stocks *Stock Advisor returns as of July 10, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie AbbVie's (NYSE: ABBV) dividend yield currently stands at nearl... | See the 10 stocks *Stock Advisor returns as of July 10, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie AbbVie's (NYSE: ABBV) dividend yield currently stands at nearl... |
22,375 | 2023-07-14 00:00:00 UTC | HSBC Initiates Coverage of Abbvie (ABBV) with Buy Recommendation | ABBV | https://www.nasdaq.com/articles/hsbc-initiates-coverage-of-abbvie-abbv-with-buy-recommendation | null | null | Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation.
Analyst Price Forecast Suggests 26.05% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The average price target... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 26.05% Upside As of July ... | Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 26.05% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.66%. | Abbvie Declares $1.48 Dividend On June 22, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 26.05% Upside As of July 5, 2023, the av... | Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 26.05% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.66%. |
22,376 | 2023-07-14 00:00:00 UTC | Notable ETF Outflow Detected - IWF, V, ABBV, DE | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwf-v-abbv-de | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $364.3 million dollar outflow -- that's a 0.5% decrease week over week (from 259,650,000 to 258,350,000). ... | Among the largest underlying components of IWF, in trading today Visa Inc (Symbol: V) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 1.1%, and Deere & Co. (Symbol: DE) is higher by about 0.4%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate in... | Among the largest underlying components of IWF, in trading today Visa Inc (Symbol: V) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 1.1%, and Deere & Co. (Symbol: DE) is higher by about 0.4%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance o... | Among the largest underlying components of IWF, in trading today Visa Inc (Symbol: V) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 1.1%, and Deere & Co. (Symbol: DE) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one sta... | Among the largest underlying components of IWF, in trading today Visa Inc (Symbol: V) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 1.1%, and Deere & Co. (Symbol: DE) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one sta... |
22,377 | 2023-07-14 00:00:00 UTC | EXCLUSIVE-MoonLake Immunotherapeutics explores sale-sources | ABBV | https://www.nasdaq.com/articles/exclusive-moonlake-immunotherapeutics-explores-sale-sources | null | null | By David Carnevali
July 14 (Reuters) - MoonLake Immunotherapeutics MLTX.O, a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
The company, which has a market value of $3.1 billion, is working with an investment bank and is ha... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... |
22,378 | 2023-07-14 00:00:00 UTC | SCHD vs. VYM: Which is the Better Dividend ETF? | ABBV | https://www.nasdaq.com/articles/schd-vs.-vym%3A-which-is-the-better-dividend-etf | null | null | The Schwab US Dividend Equity ETF (NYSEARCA:SCHD) and the Vanguard High Dividend Yield Index ETF (NYSEARCA:VYM) are two of the largest and most popular dividend ETFs in the market today. While both have lagged the broader market this year as growth stocks have taken off and left their value and dividend counterparts be... | Outside Broadcom and Texas Instruments, SCHD’s top 10 holdings include consumer staples giants like Coca-Cola (NYSE:KO) and Pepsi (NASDAQ:PEP), plus healthcare leaders like AbbVie (NYSE:ABBV) and Amgen (NYSE:AMGN) that are all well-known for their dividends. Home Depot (NYSE:HD), Pepsi, and AbbVie are also present in t... | Outside Broadcom and Texas Instruments, SCHD’s top 10 holdings include consumer staples giants like Coca-Cola (NYSE:KO) and Pepsi (NASDAQ:PEP), plus healthcare leaders like AbbVie (NYSE:ABBV) and Amgen (NYSE:AMGN) that are all well-known for their dividends. Home Depot (NYSE:HD), Pepsi, and AbbVie are also present in t... | Outside Broadcom and Texas Instruments, SCHD’s top 10 holdings include consumer staples giants like Coca-Cola (NYSE:KO) and Pepsi (NASDAQ:PEP), plus healthcare leaders like AbbVie (NYSE:ABBV) and Amgen (NYSE:AMGN) that are all well-known for their dividends. Home Depot (NYSE:HD), Pepsi, and AbbVie are also present in t... | Outside Broadcom and Texas Instruments, SCHD’s top 10 holdings include consumer staples giants like Coca-Cola (NYSE:KO) and Pepsi (NASDAQ:PEP), plus healthcare leaders like AbbVie (NYSE:ABBV) and Amgen (NYSE:AMGN) that are all well-known for their dividends. Home Depot (NYSE:HD), Pepsi, and AbbVie are also present in t... |
22,379 | 2023-07-14 00:00:00 UTC | EXCLUSIVE-MoonLake Immunotherapeutics explores sale-sources | ABBV | https://www.nasdaq.com/articles/exclusive-moonlake-immunotherapeutics-explores-sale-sources-0 | null | null | By David Carnevali
July 14 (Reuters) - MoonLake Immunotherapeutics MLTX.O, a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
The company is working with an investment bank and is having early-stage conversations with drugmak... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... | If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG NOVN.S and AbbVie Inc ABBV.N. AbbVie's Humira generates around $1 billion annually for the treatment of hidradenitis suppurativa, according to Citigroup analysts. By David Carnevali July 14 (Reuters) - MoonLake Immunotherap... |
22,380 | 2023-07-13 00:00:00 UTC | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-wisdomtree-u.s.-high-dividend-etf-dhs-a-strong-etf-right-now-7 | null | null | A smart beta exchange traded fund, the WisdomTree U.S. High Dividend ETF (DHS) debuted on 06/16/2006, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitalization weighte... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,381 | 2023-07-13 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-11 | null | null | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. This change lagged the S&P 500's 0.85% gain on the day. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 5.61%.
Heading into today, shares of the drugmaker had lost 0.92% over the past month, ... | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be July 27, 2023. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be July 27, 2023. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be July 27, 2023. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be July 27, 2023. It is also important to note the recent changes to analyst estimates for AbbVie. |
22,382 | 2023-07-13 00:00:00 UTC | 10 Best Stocks to Buy Now, Stock Market News, and Investing Q&A | ABBV | https://www.nasdaq.com/articles/10-best-stocks-to-buy-now-stock-market-news-and-investing-qa | null | null | The Invesco QQQ Trust (NASDAQ: QQQ) is up over 43% year to date, and investors are wondering what to do next. While large-cap tech names associated with artificial intelligence (AI) have been on a rampage, other stocks haven't been participating in the rally until recently. The below video providesstock market news lon... | Eric Cuka has positions in AbbVie, Bank of America, Invesco Qqq Trust, Series 1, Nike, Penn Entertainment, Tesla, UnitedHealth Group, and Walt Disney. While large-cap tech names associated with artificial intelligence (AI) have been on a rampage, other stocks haven't been participating in the rally until recently. The ... | Eric Cuka has positions in AbbVie, Bank of America, Invesco Qqq Trust, Series 1, Nike, Penn Entertainment, Tesla, UnitedHealth Group, and Walt Disney. The Motley Fool has positions in and recommends Bank of America, Nike, Tesla, Vertex Pharmaceuticals, and Walt Disney. The Motley Fool recommends STAAR Surgical and Unit... | Eric Cuka has positions in AbbVie, Bank of America, Invesco Qqq Trust, Series 1, Nike, Penn Entertainment, Tesla, UnitedHealth Group, and Walt Disney. 10 stocks we like better than Invesco Qqq Trust, Series 1 When our analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of Jul... | Eric Cuka has positions in AbbVie, Bank of America, Invesco Qqq Trust, Series 1, Nike, Penn Entertainment, Tesla, UnitedHealth Group, and Walt Disney. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Invesco Qqq Trust, Series 1 wasn't one of them! See the 10 stocks *S... |
22,383 | 2023-07-12 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-1 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,384 | 2023-07-12 00:00:00 UTC | Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs | ABBV | https://www.nasdaq.com/articles/novo-nordisk-nvo-falls-on-ema-safety-review-of-obesity-drugs | null | null | Nono Nordisk’s NVO GLP-1 receptor agonists, indicated for weight loss and treating type II diabetes, are under scrutiny by the European Medicine Agency ("EMA"). The EMA stated that its safety committee is conducting a review of obesity and diabetes care drugs, which include Ozempic (semaglutide), Saxenda (liraglutide) ... | A better-ranked stock in the same industry is AbbVie ABBV, carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for AbbVie’s 2023 earnings per share has increased from $10.97 to $10.99. During the same period, the estimate for AbbVie’s 2024 earnings has increased from $11.01 to $... | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same indust... | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same indust... | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the same indust... |
22,385 | 2023-07-12 00:00:00 UTC | Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study | ABBV | https://www.nasdaq.com/articles/incytes-incy-opzelura-meets-goal-in-phase-iii-pediatric-study | null | null | Incyte Corporation INCY recently announced positive top-line results from the late-stage TRuE-AD3 study on Opzelura (ruxolitinib cream).
TRuE-AD3 (NCT04921969) is a randomized, double-blind, vehicle-controlled phase III study evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cre... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 90 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked sto... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked sto... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 90 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. |
22,386 | 2023-07-12 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABBV, CTAS, PARA | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-abbv-ctas-para | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 35,582 contracts have traded so far, representing approximately 3.6 million underlying shares. That amounts to about 56% of ABBV's average daily trading volume over th... | Particularly high volume was seen for the $130 strike call option expiring July 21, 2023, with 2,182 contracts trading so far today, representing approximately 218,200 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symb... | Below is a chart showing ABBV's trailing twelve month trading history, with the $130 strike highlighted in orange: Cintas Corporation (Symbol: CTAS) saw options trading volume of 2,181 contracts, representing approximately 218,100 underlying shares or approximately 55.8% of CTAS's average daily trading volume over the ... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 35,582 contracts have traded so far, representing approximately 3.6 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, w... | Below is a chart showing ABBV's trailing twelve month trading history, with the $130 strike highlighted in orange: Cintas Corporation (Symbol: CTAS) saw options trading volume of 2,181 contracts, representing approximately 218,100 underlying shares or approximately 55.8% of CTAS's average daily trading volume over the ... |
22,387 | 2023-07-11 00:00:00 UTC | Morgan Stanley Reiterates Abbvie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/morgan-stanley-reiterates-abbvie-abbv-overweight-recommendation | null | null | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 25.20% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The av... | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 25.20% ... | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 25.20% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.... | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 25.20% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.... | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 25.20% Upside As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.... |
22,388 | 2023-07-11 00:00:00 UTC | Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval | ABBV | https://www.nasdaq.com/articles/roche-rhhby-blood-cancer-drug-columvi-wins-ec-approval | null | null | Roche RHHBY obtained conditional marketing authorization from the European Commission (EC) for its lymphoma drug Columvi (glofitamab).
The drug has been approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The a... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. Ligand currently sports a Zacks Rank #1 (Strong Buy) and AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased 3 cents to $10.99 for 2023. | Ligand currently sports a Zacks Rank #1 (Strong Buy) and AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article ... | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector are Ligand Pharmace... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. Ligand currently sports a Zacks Rank #1 (Strong Buy) and AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased 3 cents to $10.99 for 2023. |
22,389 | 2023-07-11 00:00:00 UTC | Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-buckle-abbvie-and-abbott-laboratories | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 7/28/23, AbbVie Inc will p... | If they do continue, the current estimated yields on annualized basis would be 3.96% for Buckle, Inc., 4.39% for AbbVie Inc, and 1.90% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symb... | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 7/28/23, AbbVie Inc will p... | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 7/28/23, AbbVie Inc will p... | If they do continue, the current estimated yields on annualized basis would be 3.96% for Buckle, Inc., 4.39% for AbbVie Inc, and 1.90% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symb... |
22,390 | 2023-07-10 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-7 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,391 | 2023-07-10 00:00:00 UTC | Cigna to add three Humira biosimilars to drug reimbursement list | ABBV | https://www.nasdaq.com/articles/cigna-to-add-three-humira-biosimilars-to-drug-reimbursement-list | null | null | July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss company Novartis to its list of preferred drugs.
The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scri... | The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scripts's formulary or its drug reimbursement list. July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss c... | The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scripts's formulary or its drug reimbursement list. July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss c... | The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scripts's formulary or its drug reimbursement list. July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss c... | The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scripts's formulary or its drug reimbursement list. July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss c... |
22,392 | 2023-07-10 00:00:00 UTC | Cigna to add three Humira biosimilars to drug reimbursement list | ABBV | https://www.nasdaq.com/articles/cigna-to-add-three-humira-biosimilars-to-drug-reimbursement-list-0 | null | null | Adds background on drugs, PBM, in paragraphs 3-5
July 10 (Reuters) - Cigna Group's CI.N Express Scripts will add three biosimilars of AbbVie's ABBV.N blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday.
The biosimilars include Hyrimoz and an unbranded version of Humira from... | Adds background on drugs, PBM, in paragraphs 3-5 July 10 (Reuters) - Cigna Group's CI.N Express Scripts will add three biosimilars of AbbVie's ABBV.N blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. The biosimilars include Hyrimoz and an unbranded version of Humira from... | Adds background on drugs, PBM, in paragraphs 3-5 July 10 (Reuters) - Cigna Group's CI.N Express Scripts will add three biosimilars of AbbVie's ABBV.N blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. Express Scripts, the pharmacy benefits management (PBM) business of Cig... | Adds background on drugs, PBM, in paragraphs 3-5 July 10 (Reuters) - Cigna Group's CI.N Express Scripts will add three biosimilars of AbbVie's ABBV.N blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. Express Scripts, the pharmacy benefits management (PBM) business of Cig... | Adds background on drugs, PBM, in paragraphs 3-5 July 10 (Reuters) - Cigna Group's CI.N Express Scripts will add three biosimilars of AbbVie's ABBV.N blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. The biosimilars include Hyrimoz and an unbranded version of Humira from... |
22,393 | 2023-07-10 00:00:00 UTC | Bausch Health (BHC) Secures $600M Financing Facility, Stock Up | ABBV | https://www.nasdaq.com/articles/bausch-health-bhc-secures-%24600m-financing-facility-stock-up | null | null | Bausch Health Companies Inc. BHC shares were up 8.45% after it announced a crucial development that will significantly enhance its liquidity.
Bausch Health, in collaboration with leading investment firm KKR, has established a non-recourse financing facility worth $600 million. This facility, provided by KKR and its cre... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. | While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report To read this a... | Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector are Ligand Phar... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. |
22,394 | 2023-07-10 00:00:00 UTC | Novartis (NVS) Entresto Patent Faces Setback, Stock Down | ABBV | https://www.nasdaq.com/articles/novartis-nvs-entresto-patent-faces-setback-stock-down | null | null | Novartis NVS recently received an unfavorable ruling from the U.S. District Court for the District of Delaware regarding the validity of a patent covering its flagship product, Entresto.
This patent, which includes the combination of sacubitril and valsartan, is set to expire in 2025 with its pediatric exclusivity. Des... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ran... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ran... | Some better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND and AbbVie ABBV. While Ligand currently sports a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy). Over the past 60 days, earnings estimates for ABBV have increased by 3 cents to $10.99 for 2023. |
22,395 | 2023-07-09 00:00:00 UTC | PEP, ABBV, or GM: Which Value Stock Could Offer the Highest Upside? | ABBV | https://www.nasdaq.com/articles/pep-abbv-or-gm%3A-which-value-stock-could-offer-the-highest-upside | null | null | The fear of the U.S. Federal Reserve resuming interest rate hikes soon has reinforced fears of an impending recession. Investors with a long-term horizon could benefit by looking at attractive value stocks – stocks of companies trading at lower prices than what the fundamentals suggest. Using TipRanks’ Stock Comparison... | Analysts see higher upside potential in AbbVie from current levels, with the pullback in the stock offering an attractive buying opportunity for the long term. Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value sto... | Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. AbbVie (NYSE:ABBV) Shares of AbbVie have been under pressure due to investors’ concerns ab... | Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. AbbVie (NYSE:ABBV) Shares of AbbVie have been under pressure due to investors’ concerns ab... | Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. AbbVie (NYSE:ABBV) Shares of AbbVie have been under pressure due to investors’ concerns ab... |
22,396 | 2023-07-08 00:00:00 UTC | 3 No-Brainer Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-no-brainer-stocks-you-can-buy-right-now | null | null | Some decisions are hard. Others, however, are so easy that they require much less thought.
Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter category. Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-bra... | Patent cliffs for therapies that generate billions in sales can be hard to navigate for drugmakers, and the market doesn't seem too confident that AbbVie will do a good job of it. These medicines point to a deeper reason to trust that AbbVie's prospects are just fine: the company's innovative capabilities that have yie... | Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer stocks to buy right now. "Be greedy when others are fearful" Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie isn't currently popular with investors. It's no wonder: AbbVie's financial results are ... | Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer stocks to buy right now. "Be greedy when others are fearful" Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie isn't currently popular with investors. It's no wonder: AbbVie's financial results are ... | Patent cliffs for therapies that generate billions in sales can be hard to navigate for drugmakers, and the market doesn't seem too confident that AbbVie will do a good job of it. Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer stocks to buy right ... |
22,397 | 2023-07-08 00:00:00 UTC | ABBV Quantitative Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-quantitative-stock-analysis-2 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,398 | 2023-07-07 00:00:00 UTC | After Hours Most Active for Jul 7, 2023 : INTC, AAPL, BAC, KO, TLT, QQQ, GOOGL, PLTR, RIVN, ABBV, HL, RLJ | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-jul-7-2023-%3A-intc-aapl-bac-ko-tlt-qqq-googl-pltr-rivn-abbv-hl | null | null | The NASDAQ 100 After Hours Indicator is up 3.48 to 15,040.33. The total After hours volume is currently 80,191,351 shares traded.
The following are the most active stocks for the after hours session:
Intel Corporation (INTC) is +0.01 at $31.86, with 5,468,000 shares traded. INTC's current last sale is 101.14% of the ... | AbbVie Inc. (ABBV) is unchanged at $135.50, with 1,127,388 shares traded. ABBV's current last sale is 81.14% of the target price of $167. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | AbbVie Inc. (ABBV) is unchanged at $135.50, with 1,127,388 shares traded. ABBV's current last sale is 81.14% of the target price of $167. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | AbbVie Inc. (ABBV) is unchanged at $135.50, with 1,127,388 shares traded. ABBV's current last sale is 81.14% of the target price of $167. The total After hours volume is currently 80,191,351 shares traded. | AbbVie Inc. (ABBV) is unchanged at $135.50, with 1,127,388 shares traded. ABBV's current last sale is 81.14% of the target price of $167. The NASDAQ 100 After Hours Indicator is up 3.48 to 15,040.33. |
22,399 | 2023-07-07 00:00:00 UTC | 2 Struggling Dividend Growth Stocks That Could Make You Richer | ABBV | https://www.nasdaq.com/articles/2-struggling-dividend-growth-stocks-that-could-make-you-richer | null | null | Despite lingering economic issues, the broader stock market has recovered this year. But some companies are failing to keep up for a variety of reasons. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. Both healthcare giants are encount... | Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. However, AbbVie and Amgen have enough in the tank to survive their current ordeals and continue doing what they do best over the long run: reward shareholders with solid dividend increase... | And with a yield of 4.39% and a cash payout ratio of 43%, AbbVie remains an excellent dividend growth stock for income-seeking investors. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. However, AbbVie and Amgen have enough in the tank... | Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. However, AbbVie and Amgen have enough in the tank to survive their current ordeals and continue doing what they do best over the long run: reward shareholders with solid dividend increase... | Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. However, AbbVie and Amgen have enough in the tank to survive their current ordeals and continue doing what they do best over the long run: reward shareholders with solid dividend increase... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.